Identification of HLA-A*0201-restricted cytotoxic T lymphocyte epitope from proliferating cell nuclear antigen. 2011

Wei Xu, and Hui-Zhong Li, and Jun-Jie Liu, and Zhen Guo, and Bao-Fu Zhang, and Fei-Fei Chen, and Dong-Sheng Pei, and Jun-Nian Zheng
Laboratory of Biological Cancer Therapy, Surgical oncology, Xuzhou Medical College, 84 West Huai-hai Road, Xuzhou 221002, Jiangsu, People's Republic of China.

Peptide-based immunotherapy strategies appear promising as an approach to successfully induce an antitumor immune response and prolong survival in patients with various cancers. Protein antigens and their specific epitopes are formulation targets for anti-tumor vaccines. Bioinformatical approaches to predict major histocompatibility complex binding peptides can facilitate the resource-consuming effort of T cell epitope identification. Proliferating cell nuclear antigen including Ki-67 and PCNA, associated with the proliferation process of the cell, seems to be an attractive new target for tumor-specific immunotherapy. In this study, we predicted seven HLA-A*0201-restricted CTL candidate epitope of Ki-67 and eight epitope of PCNA by computer algorithm SYFPEITHI, BIMAS, and IEDB_ANN. Subsequently, biological functions of these peptides were tested by experiments in vitro. We found Ki-67((280-288)) (LQGETQLLV) had the strongest binding-affinity with HLA-A*0201. Further study revealed that Ki-67((280-288)) increased the frequency of IFN-γ-producing T cells compared to a negative peptide. Because Ki-67 was broadly expressed in most advanced malignant tumors, indicating a potential anti-tumor application in the future.

UI MeSH Term Description Entries
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013274 Stomach Neoplasms Tumors or cancer of the STOMACH. Cancer of Stomach,Gastric Cancer,Gastric Neoplasms,Stomach Cancer,Cancer of the Stomach,Gastric Cancer, Familial Diffuse,Neoplasms, Gastric,Neoplasms, Stomach,Cancer, Gastric,Cancer, Stomach,Cancers, Gastric,Cancers, Stomach,Gastric Cancers,Gastric Neoplasm,Neoplasm, Gastric,Neoplasm, Stomach,Stomach Cancers,Stomach Neoplasm
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal
D015234 HLA-A Antigens Polymorphic class I human histocompatibility (HLA) surface antigens present on almost all nucleated cells. At least 20 antigens have been identified which are encoded by the A locus of multiple alleles on chromosome 6. They serve as targets for T-cell cytolytic responses and are involved with acceptance or rejection of tissue/organ grafts. Antigens, HLA-A,HLA-A,Antigens, HLA A,HLA A Antigens
D015789 HLA-A2 Antigen A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*02 allele family. HLA Class I Histocompatibility Antigen, A-2 alpha Chain,HLA-A2,Antigen, HLA-A2,HLA A2 Antigen,HLA Class I Histocompatibility Antigen, A 2 alpha Chain

Related Publications

Wei Xu, and Hui-Zhong Li, and Jun-Jie Liu, and Zhen Guo, and Bao-Fu Zhang, and Fei-Fei Chen, and Dong-Sheng Pei, and Jun-Nian Zheng
May 2003, Clinical cancer research : an official journal of the American Association for Cancer Research,
Wei Xu, and Hui-Zhong Li, and Jun-Jie Liu, and Zhen Guo, and Bao-Fu Zhang, and Fei-Fei Chen, and Dong-Sheng Pei, and Jun-Nian Zheng
December 2009, Cancer immunology, immunotherapy : CII,
Wei Xu, and Hui-Zhong Li, and Jun-Jie Liu, and Zhen Guo, and Bao-Fu Zhang, and Fei-Fei Chen, and Dong-Sheng Pei, and Jun-Nian Zheng
December 2006, Cancer immunology, immunotherapy : CII,
Wei Xu, and Hui-Zhong Li, and Jun-Jie Liu, and Zhen Guo, and Bao-Fu Zhang, and Fei-Fei Chen, and Dong-Sheng Pei, and Jun-Nian Zheng
February 2024, European journal of microbiology & immunology,
Wei Xu, and Hui-Zhong Li, and Jun-Jie Liu, and Zhen Guo, and Bao-Fu Zhang, and Fei-Fei Chen, and Dong-Sheng Pei, and Jun-Nian Zheng
October 2011, International journal of oncology,
Wei Xu, and Hui-Zhong Li, and Jun-Jie Liu, and Zhen Guo, and Bao-Fu Zhang, and Fei-Fei Chen, and Dong-Sheng Pei, and Jun-Nian Zheng
January 2002, International journal of cancer,
Wei Xu, and Hui-Zhong Li, and Jun-Jie Liu, and Zhen Guo, and Bao-Fu Zhang, and Fei-Fei Chen, and Dong-Sheng Pei, and Jun-Nian Zheng
November 2006, The Journal of general virology,
Wei Xu, and Hui-Zhong Li, and Jun-Jie Liu, and Zhen Guo, and Bao-Fu Zhang, and Fei-Fei Chen, and Dong-Sheng Pei, and Jun-Nian Zheng
August 2013, Journal of neuro-oncology,
Wei Xu, and Hui-Zhong Li, and Jun-Jie Liu, and Zhen Guo, and Bao-Fu Zhang, and Fei-Fei Chen, and Dong-Sheng Pei, and Jun-Nian Zheng
May 2013, Cellular & molecular immunology,
Wei Xu, and Hui-Zhong Li, and Jun-Jie Liu, and Zhen Guo, and Bao-Fu Zhang, and Fei-Fei Chen, and Dong-Sheng Pei, and Jun-Nian Zheng
March 2013, Vaccine,
Copied contents to your clipboard!